Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 566

1.

Photokeratitis among restaurant workers: A case series.

Stripp MP, Dulaney AR, Beuhler MC, Langley RL.

Am J Ind Med. 2018 Jul 11. doi: 10.1002/ajim.22875. [Epub ahead of print]

PMID:
29998493
2.

Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database.

Warren RB, Reich K, Langley RG, Strober B, Gladman D, Deodhar A, Bachhuber T, Bao W, Altemeyer E, Hussain S, Safi J Jr.

Br J Dermatol. 2018 Jun 21. doi: 10.1111/bjd.16901. [Epub ahead of print]

PMID:
29927479
3.

Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis.

Ma G, Xie R, Strober B, Langley R, Ito K, Krishnaswami S, Wolk R, Valdez H, Rottinghaus S, Tallman A, Gupta P.

Clin Pharmacol Drug Dev. 2018 Jun 1. doi: 10.1002/cpdd.471. [Epub ahead of print]

PMID:
29856518
4.

ATP11B mediates platinum resistance in ovarian cancer.

Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings NB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJ, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK.

J Clin Invest. 2018 May 29. pii: 122301. doi: 10.1172/JCI122301. [Epub ahead of print] No abstract available.

5.

The direction of travel to better outcomes for patients with oesophago-gastric cancer.

Langley RE.

J Thorac Dis. 2018 Mar;10(3):1236-1238. doi: 10.21037/jtd.2018.03.23. No abstract available.

6.

Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study.

Hewitt LC, Inam IZ, Saito Y, Yoshikawa T, Quaas A, Hoelscher A, Bollschweiler E, Fazzi GE, Melotte V, Langley RE, Nankivell M, Cunningham D, Allum W, Hutchins GG, Grabsch HI.

Eur J Cancer. 2018 May;94:104-114. doi: 10.1016/j.ejca.2018.02.014. Epub 2018 Mar 20.

7.

Unsupervised Analysis of Transcriptomics in Bacterial Sepsis Across Multiple Datasets Reveals Three Robust Clusters.

Sweeney TE, Azad TD, Donato M, Haynes WA, Perumal TM, Henao R, Bermejo-Martin JF, Almansa R, Tamayo E, Howrylak JA, Choi A, Parnell GP, Tang B, Nichols M, Woods CW, Ginsburg GS, Kingsmore SF, Omberg L, Mangravite LM, Wong HR, Tsalik EL, Langley RJ, Khatri P.

Crit Care Med. 2018 Jun;46(6):915-925. doi: 10.1097/CCM.0000000000003084.

PMID:
29537985
8.

Aspirin: 120 years of innovation. A report from the 2017 Scientific Conference of the International Aspirin Foundation, 14 September 2017, Charité, Berlin.

Walker J, Hutchison P, Ge J, Zhao D, Wang Y, Rothwell PM, Gaziano JM, Chan A, Burn J, Chia J, Langley R, O'Donnell V, Rocca B, Hawkey C.

Ecancermedicalscience. 2018 Feb 20;12:813. doi: 10.3332/ecancer.2018.813. eCollection 2018.

9.

Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.

Papp KA, Gordon KB, Langley RG, Lebwohl MG, Gottlieb AB, Rastogi S, Pillai R, Israel RJ.

Br J Dermatol. 2018 Feb 28. doi: 10.1111/bjd.16464. [Epub ahead of print]

PMID:
29488226
10.

Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial.

Davarzani N, Hutchins GGA, West NP, Hewitt LC, Nankivell M, Cunningham D, Allum WH, Smyth E, Valeri N, Langley RE, Grabsch HI.

Histopathology. 2018 Jun;72(7):1180-1188. doi: 10.1111/his.13491. Epub 2018 Mar 25.

11.

A community approach to mortality prediction in sepsis via gene expression analysis.

Sweeney TE, Perumal TM, Henao R, Nichols M, Howrylak JA, Choi AM, Bermejo-Martin JF, Almansa R, Tamayo E, Davenport EE, Burnham KL, Hinds CJ, Knight JC, Woods CW, Kingsmore SF, Ginsburg GS, Wong HR, Parnell GP, Tang B, Moldawer LL, Moore FE, Omberg L, Khatri P, Tsalik EL, Mangravite LM, Langley RJ.

Nat Commun. 2018 Feb 15;9(1):694. doi: 10.1038/s41467-018-03078-2.

12.

Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P).

Langley RG, Papp K, Gooderham M, Zhang L, Mallinckrodt C, Agada N, Blauvelt A, Foley P, Polzer P; of the IXORA-P Investigators.

Br J Dermatol. 2018 Jun;178(6):1315-1323. doi: 10.1111/bjd.16426. Epub 2018 May 15.

PMID:
29405255
13.

Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform.

Gilbert DC, Duong T, Sydes M, Bara A, Clarke N, Abel P, James N, Langley R, Parmar M; STAMPEDE and PATCH Trial Management Groups.

BJU Int. 2018 May;121(5):680-683. doi: 10.1111/bju.14153. Epub 2018 Feb 28. No abstract available.

PMID:
29388336
14.

Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.

Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, Merola JF, Ryan C, Siegel MP, Weinberg JM, Wu JJ, Van Voorhees AS.

J Am Acad Dermatol. 2018 Feb;78(2):383-394. doi: 10.1016/j.jaad.2017.06.043. Review.

PMID:
29332708
15.

Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies.

Pariser D, Frankel E, Schlessinger J, Poulin Y, Vender R, Langley RG, Meng X, Guana A, Nyirady J.

Dermatol Ther (Heidelb). 2018 Mar;8(1):17-32. doi: 10.1007/s13555-017-0211-4. Epub 2017 Dec 7.

16.

Neoadjuvant chemotherapy in oesophageal adenocarcinoma - Authors' reply.

Alderson D, Nankivell M, Langley R, Cunningham D.

Lancet Oncol. 2017 Nov;18(11):e641. doi: 10.1016/S1470-2045(17)30776-3. Epub 2017 Oct 31. No abstract available.

PMID:
29208395
17.

Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab.

Warren RB, Brnabic A, Saure D, Langley RG, See K, Wu JJ, Schacht A, Mallbris L, Nast A.

Br J Dermatol. 2018 May;178(5):1064-1071. doi: 10.1111/bjd.16140. Epub 2018 Mar 1.

PMID:
29171861
18.

Multi-arm Clinical Trials - Teams within Teams.

Langley RE, Mason MD.

Clin Oncol (R Coll Radiol). 2017 Dec;29(12):787-788. doi: 10.1016/j.clon.2017.10.001. Epub 2017 Oct 27. No abstract available.

19.

Pharmacokinetics, Immunogenicity, and Efficacy of Etanercept in Pediatric Patients With Moderate to Severe Plaque Psoriasis.

Langley RG, Kasichayanula S, Trivedi M, Aras GA, Kaliyaperumal A, Yuraszeck T, Gibbs J, Gibbs M, Kricorian G, Paller AS.

J Clin Pharmacol. 2017 Nov 6. doi: 10.1002/jcph.1029. [Epub ahead of print]

PMID:
29106714
20.

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, Goyal K, Lawson F, Langholff W, Hopkins L, Fakharzadeh S, Srivastava B, Menter A.

J Am Acad Dermatol. 2018 Jan;78(1):70-80. doi: 10.1016/j.jaad.2017.08.051. Epub 2017 Nov 6.

21.

North Carolina Toxic Substance Incidents Program 2010-2015: Identifying Areas for Injury Prevention Efforts.

Eiffert S, Etienne S, Hirsch A, Langley R.

Toxics. 2017 Aug 6;5(3). pii: E16. doi: 10.3390/toxics5030016.

22.

No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis.

Strober BE, Langley RGB, Menter A, Magid M, Porter B, Fox T, Safi J Jr, Papavassilis C.

Br J Dermatol. 2018 Feb;178(2):e105-e107. doi: 10.1111/bjd.16051. Epub 2017 Dec 22. No abstract available.

PMID:
28991372
23.

Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy.

Smyth E, Zhang S, Cunningham D, Wotherspoon A, Soong R, Peckitt C, Valeri N, Fassan M, Rugge M, Okines A, Allum W, Stenning S, Nankivell M, Langley R, Tan P.

Clin Cancer Res. 2017 Dec 15;23(24):7543-7549. doi: 10.1158/1078-0432.CCR-16-3142. Epub 2017 Oct 2.

PMID:
28972045
24.

Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry.

Fiorentino D, Ho V, Lebwohl MG, Leite L, Hopkins L, Galindo C, Goyal K, Langholff W, Fakharzadeh S, Srivastava B, Langley RG.

J Am Acad Dermatol. 2017 Nov;77(5):845-854.e5. doi: 10.1016/j.jaad.2017.07.013. Epub 2017 Sep 8.

25.

Staphylococcal enterotoxin-like X (SElX) is a unique superantigen with functional features of two major families of staphylococcal virulence factors.

Langley RJ, Ting YT, Clow F, Young PG, Radcliff FJ, Choi JM, Sequeira RP, Holtfreter S, Baker H, Fraser JD.

PLoS Pathog. 2017 Sep 7;13(9):e1006549. doi: 10.1371/journal.ppat.1006549. eCollection 2017 Sep.

26.

Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression.

Dalton HJ, Pradeep S, McGuire M, Hailemichael Y, Ma S, Lyons Y, Armaiz-Pena GN, Previs RA, Hansen JM, Rupaimoole R, Gonzalez-Villasana V, Cho MS, Wu SY, Mangala LS, Jennings NB, Hu W, Langley R, Mu H, Andreeff M, Bar-Eli M, Overwijk W, Ram P, Lopez-Berestein G, Coleman RL, Sood AK.

Clin Cancer Res. 2017 Nov 15;23(22):7034-7046. doi: 10.1158/1078-0432.CCR-17-0647. Epub 2017 Aug 29.

PMID:
28855350
27.

Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols.

Parmar MK, Sydes MR, Cafferty FH, Choodari-Oskooei B, Langley RE, Brown L, Phillips PP, Spears MR, Rowley S, Kaplan R, James ND, Maughan T, Paton N, Royston PJ.

Clin Trials. 2017 Oct;14(5):451-461. doi: 10.1177/1740774517725697. Epub 2017 Aug 22.

28.

Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results.

Langley RGB, Reich K, Papavassilis C, Fox T, Gong Y, Gu Ttner A.

J Drugs Dermatol. 2017 Aug 1;16(8):734-741.

PMID:
28809988
29.

Validation of psychometric properties and development of response criteria for the Psoriasis Symptoms and Signs Diary (PSSD): results from a phase III clinical trial.

Armstrong A, Puig L, Langley R, Tsai TF, Song M, Wasfi Y, Jiang J, Li S, Han C.

J Dermatolog Treat. 2017 Aug 11:1-31. doi: 10.1080/09546634.2017.1364694. [Epub ahead of print]

PMID:
28797188
30.

Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.

Alderson D, Cunningham D, Nankivell M, Blazeby JM, Griffin SM, Crellin A, Grabsch HI, Langer R, Pritchard S, Okines A, Krysztopik R, Coxon F, Thompson J, Falk S, Robb C, Stenning S, Langley RE.

Lancet Oncol. 2017 Sep;18(9):1249-1260. doi: 10.1016/S1470-2045(17)30447-3. Epub 2017 Aug 4.

31.

North Carolina State Agencies Working to Prevent Agricultural Injuries and Illnesses.

Langley R, Hirsch A, Cullen R, Allran J, Woody R, Bell D.

J Agromedicine. 2017;22(4):358-363. doi: 10.1080/1059924X.2017.1353468.

PMID:
28704143
32.

Fatal and non-fatal animal-related injuries and illnesses to workers, United States, 2011-2014.

Barros N, Langley R.

Am J Ind Med. 2017 Sep;60(9):776-788. doi: 10.1002/ajim.22744. Epub 2017 Jul 5.

PMID:
28677842
33.

Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.

Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, Jiang J, Li S, Puig L.

Br J Dermatol. 2018 Jan;178(1):114-123. doi: 10.1111/bjd.15750. Epub 2017 Oct 10.

PMID:
28635018
34.

Early Diagnosis of Sepsis: Is an Integrated Omics Approach the Way Forward?

Langley RJ, Wong HR.

Mol Diagn Ther. 2017 Oct;21(5):525-537. doi: 10.1007/s40291-017-0282-z. Review.

PMID:
28624903
35.

The curious incident of groaning in the night-time.

Langley RJ, Hill L, Hill EA, Urquhart DS.

Breathe (Sheff). 2017 Jun;13(2):123-126. doi: 10.1183/20734735.017816.

36.

From the Children's Oncology Group: Evidence-Based Recommendations for PEG-Asparaginase Nurse Monitoring, Hypersensitivity Reaction Management, and Patient/Family Education.

Woods D, Winchester K, Towerman A, Gettinger K, Carey C, Timmermann K, Langley R, Browne E.

J Pediatr Oncol Nurs. 2017 Nov/Dec;34(6):387-396. doi: 10.1177/1043454217713455. Epub 2017 Jun 10. Review.

37.

Polypill is not just for cardiovascular disease.

Cafferty FH, Langley RE.

BMJ. 2017 Jun 7;357:j2733. doi: 10.1136/bmj.j2733. No abstract available.

PMID:
28592412
38.

The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.

Cascone T, Xu L, Lin HY, Liu W, Tran HT, Liu Y, Howells K, Haddad V, Hanrahan E, Nilsson MB, Cortez MA, Giri U, Kadara H, Saigal B, Park YY, Peng W, Lee JS, Ryan AJ, Jüergensmeier JM, Herbst RS, Wang J, Langley RR, Wistuba II, Lee JJ, Heymach JV.

Clin Cancer Res. 2017 Sep 15;23(18):5489-5501. doi: 10.1158/1078-0432.CCR-16-3216. Epub 2017 May 30.

PMID:
28559461
39.

Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis.

Blauvelt A, Reich K, Warren RB, Szepietowski JC, Sigurgeirsson B, Tyring SK, Messina I, Bhosekar V, Oliver J, Papavassilis C, Frueh J, Langley RGB.

Br J Dermatol. 2017 Sep;177(3):879-881. doi: 10.1111/bjd.15656. Epub 2017 Aug 9. No abstract available.

PMID:
28498514
40.

Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma - Authors' reply.

Smyth EC, Allum WH, Rowley S, Langley RE, Cunningham D.

Lancet Oncol. 2017 May;18(5):e244. doi: 10.1016/S1470-2045(17)30261-9. No abstract available.

PMID:
28495289
41.

Whole brain radiotherapy for non-small cell lung cancer - Authors' reply.

Langley RE, Nankivell M, Barton R, Faivre-Finn C, Mulvenna P; QUARTZ trial management group.

Lancet. 2017 Apr 8;389(10077):1395-1396. doi: 10.1016/S0140-6736(17)30892-9. No abstract available.

PMID:
28402818
42.

Gestational Exposure to Sidestream (Secondhand) Cigarette Smoke Promotes Transgenerational Epigenetic Transmission of Exacerbated Allergic Asthma and Bronchopulmonary Dysplasia.

Singh SP, Chand HS, Langley RJ, Mishra N, Barrett T, Rudolph K, Tellez C, Filipczak PT, Belinsky S, Saeed AI, Sheybani A, Exil V, Agarwal H, Sidhaye VK, Sussan T, Biswal S, Sopori M.

J Immunol. 2017 May 15;198(10):3815-3822. doi: 10.4049/jimmunol.1700014. Epub 2017 Apr 5.

43.

Human genetic and metabolite variation reveals that methylthioadenosine is a prognostic biomarker and an inflammatory regulator in sepsis.

Wang L, Ko ER, Gilchrist JJ, Pittman KJ, Rautanen A, Pirinen M, Thompson JW, Dubois LG, Langley RJ, Jaslow SL, Salinas RE, Rouse DC, Moseley MA, Mwarumba S, Njuguna P, Mturi N; Wellcome Trust Case Control Consortium 2; Kenyan Bacteraemia Study Group, Williams TN, Scott JA, Hill AV, Woods CW, Ginsburg GS, Tsalik EL, Ko DC.

Sci Adv. 2017 Mar 8;3(3):e1602096. doi: 10.1126/sciadv.1602096. eCollection 2017 Mar.

44.

Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).

Menter A, Warren RB, Langley RG, Merola JF, Kerr LN, Dennehy EB, Shrom D, Amato D, Okubo Y, Reich K.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1686-1692. doi: 10.1111/jdv.14237. Epub 2017 Apr 26.

PMID:
28322474
45.

Co-enrolment of Participants into Multiple Cancer Trials: Benefits and Challenges.

Cafferty FH, Coyle C, Rowley S, Berkman L, MacKensie M, Langley RE.

Clin Oncol (R Coll Radiol). 2017 Jul;29(7):e126-e133. doi: 10.1016/j.clon.2017.02.014. Epub 2017 Mar 14. Review.

46.

Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.

Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, Fassan M, Rugge M, Valeri N, Okines A, Hewish M, Allum W, Stenning S, Nankivell M, Langley R, Cunningham D.

JAMA Oncol. 2017 Sep 1;3(9):1197-1203. doi: 10.1001/jamaoncol.2016.6762.

47.

How Should Oxygen Supplementation Be Guided by Pulse Oximetry in Children: Do We Know the Level?

Langley R, Cunningham S.

Front Pediatr. 2017 Jan 27;4:138. doi: 10.3389/fped.2016.00138. eCollection 2016. Review.

48.

Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.

Cunningham D, Stenning SP, Smyth EC, Okines AF, Allum WH, Rowley S, Stevenson L, Grabsch HI, Alderson D, Crosby T, Griffin SM, Mansoor W, Coxon FY, Falk SJ, Darby S, Sumpter KA, Blazeby JM, Langley RE.

Lancet Oncol. 2017 Mar;18(3):357-370. doi: 10.1016/S1470-2045(17)30043-8. Epub 2017 Feb 3.

49.

Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study.

Frouws MA, Bastiaannet E, Langley RE, Chia WK, van Herk-Sukel MP, Lemmens VE, Putter H, Hartgrink HH, Bonsing BA, Van de Velde CJ, Portielje JE, Liefers GJ.

Br J Cancer. 2017 Jan;116(3):405-413. doi: 10.1038/bjc.2016.425. Epub 2017 Jan 10.

50.

Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.

Reich K, Leonardi C, Langley RG, Warren RB, Bachelez H, Romiti R, Ohtsuki M, Xu W, Acharya N, Solotkin K, Colombel JF, Hardin DS.

J Am Acad Dermatol. 2017 Mar;76(3):441-448.e2. doi: 10.1016/j.jaad.2016.10.027. Epub 2016 Dec 24. Erratum in: J Am Acad Dermatol. 2017 Aug;77(2):390-390.e1.

Supplemental Content

Loading ...
Support Center